Under the Inflation Reduction Act, Medicare will be able to negotiate prices for a limited number of high-cost prescription drugs. This article describes a loophole in the rules around the selection of drugs for negotiation. The authors propose a solution that may reduce perverse incentives for drug manufacturers and improve the ability of Medicare to optimize savings.